Advanced treatment
Immunotherapy
Treatment that helps the immune system recognise and attack cancer cells, usually through immune checkpoint inhibitors.

Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
What is it?
Immunotherapy works through the immune system so the response pattern can be different from chemotherapy.
Some patients experience a lasting response, others do not get the expected benefits.
Markers such as PD-L1 and MSI/MMR are often part of the consideration.
Antibodies inhibit signals that suppress the immune system so that T cells become more active against cancer cells.
How it works
Antibodies inhibit signals that suppress the immune system so that T cells become more active against cancer cells.
Position in the treatment pathway: Can be first-line therapy in certain groups, therapy after other therapies, or in combination with chemotherapy.

Which cancers is it usually discussed for?

Lung Cancer
Lung cancer is divided into non-small-cell and small-cell groups, and molecular markers strongly shape which treatment options are discussed.
Open cancer page
Stomach Cancer
Stomach cancer is most often adenocarcinoma, and HER2, PD-L1, MSI/MMR and CLDN18.2 status can change which treatment options are discussed.
Open cancer page
Lymphoma
Lymphoma is a malignancy of the lymphatic system with many subtypes, and accurate pathological classification determines the direction of treatment.
Open cancer page
Multiple Myeloma
Multiple myeloma is a malignancy of plasma cells in the bone marrow, with cytogenetic markers that matter when treatment strategy is considered.
Open cancer page
Usually considered
- Relevant markers according to the indications discussed.
- General condition is adequate, without active uncontrolled autoimmune disease.
Usually not a candidate
- History of certain high-risk autoimmune diseases.
- The need for high doses of immunosuppressant medication needs to be discussed with your doctor.
What is the process like?
Preparation 1
History of autoimmune disease and lung disease.
Preparation 2
Basic laboratory examination.
Preparation 3
Discussion of the risk of reactions related to the immune system.
Monitoring
Monitor for systemic symptoms at each visit.
All preparation
- History of autoimmune disease and lung disease.
- Basic laboratory examination.
- Discussion of the risk of reactions related to the immune system.
All monitoring
- Monitor for systemic symptoms at each visit.
- Periodic laboratory tests, including thyroid function.
Risks and points to watch
Side-effect notes, not a complete list
- Reactions related to the immune system can occur in the skin, intestines, lungs, liver or endocrine glands.
- Symptoms such as shortness of breath or severe diarrhea need to be checked immediately.
- Some side effects may appear after therapy is completed.
What needs to be checked?

PD-L1 immunohistochemistry
A staining test to assess PD-L1 expression and its score.
View test
MMR immunohistochemistry
A test of four DNA repair proteins to assess dMMR status.
View test
MSI PCR
A molecular test to assess microsatellite instability.
View test
Blood laboratory tests
Routine blood tests to assess general condition, organ function, and selected markers.
View test
CT scan
Cross-sectional imaging to assess tumour size, location, and nearby organs.
View test
PD-L1
PD-L1 is a protein that can help cancer cells evade the immune system.
View biomarker
MSI / MMR
Cells have a DNA repair system.
View biomarker
Cost and access
Cost figures depend heavily on location, facility and payer. We do not show estimated figures on this page; what can be prepared first are the questions.
Pembrolizumab
Anti-PD-1 antibodies
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Nivolumab
Anti-PD-1 antibodies
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Ipilimumab
Anti-CTLA-4 antibodies
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Atezolizumab
Anti-PD-L1 antibodies
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Durvalumab
Anti-PD-L1 antibodies
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Cemiplimab
Anti-PD-1 antibodies
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Dostarlimab
Anti-PD-1 antibodies
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Rituximab
Anti-CD20 monoclonal antibody
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Glofitamab
CD20xCD3 bispecific antibody
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Daratumumab
Anti-CD38 monoclonal antibody
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Teclistamab
BCMAxCD3 bispecific antibody
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Providers and clinical trials
Access status not yet verified
NCT04267848Phase 3Immunotherapy
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Cancer | Immunotherapy, Chemotherapy
United States, Guam1151 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04267848Not verified
NCT05139017Phase 2 / Phase 3Immunotherapy
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Lymphoma | Immunotherapy, Chemotherapy
United States, Argentina, Australia +23135 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05139017Not verified
NCT05633615Phase 2CAR-T cell therapy
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lymphoma | biomarker: CD19 | CAR-T cell therapy, Immunotherapy, Chemotherapy
United States95 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05633615Not verified
NCT05675410Phase 3Combination regimen
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lymphoma | Immunotherapy, Radiotherapy, Chemotherapy
United States, Canada, Puerto Rico417 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05675410Not verified
NCT05947851Phase 3Combination regimen
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Lymphoma | Immunotherapy, Targeted therapy
United States, Argentina, Australia +1999 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05947851Not verified
NCT06170788Phase 3Immunotherapy
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Lung Cancer | biomarker: PD-L1 | Immunotherapy, Perawatan suportif dan paliatif
United States, Argentina, Australia +23220 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06170788Not verified
Questions for the doctor
- What is the basis for considering immunotherapy in this case?
- What symptoms should be reported immediately?
- What is the plan for regular check-ups during therapy?
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Is Immunotherapy relevant for my case?
Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.
Upload reports
Photos or PDFs of pathology, biomarkers, imaging and treatment history.
Case structured
Documents are turned into a structured case summary.
Navigator review
A human navigator checks completeness before anything is shared.
Provider review
With your consent, the case is discussed with providers for assessment and a written quote.
Is Immunotherapy relevant for my case?
Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
You just read about Immunotherapy. Next:

Hasil CLDN18.2 positif pada kanker lambung: apa artinya?
9 min read

DLBCL kambuh? Kapan terapi CAR-T mulai dibahas
9 min read

Clinical trials mentioning this category
103 public registry records mention this category.

Upload Medical Reports
Find out whether this category is worth asking about for your case, using structured documents.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- BCMA
Biomarker
Reason: Related through a biomarker
- CD19
Biomarker
Reason: Related through a biomarker
- Amivantamab
Drug
Reason: Uses this drug
- Atezolizumab
Drug
Reason: Uses this drug
- onkologi-medis
Service
Reason: Related to this page
- What biomarker results do and do not say
Explainer
Reason: Related to this page
To check
- CT scan
Diagnostic test
Reason: Memerlukan pemeriksaan
- MMR immunohistochemistry
Diagnostic test
Reason: Memerlukan pemeriksaan
- Gastric cancer after chemotherapy no longer gives results
Decision situation
Reason: Mungkin memerlukan
- Newly diagnosed lung cancer
Decision situation
Reason: Mungkin memerlukan
- Blood laboratory tests
Diagnostic test
Reason: Memerlukan pemeriksaan
- MSI PCR
Diagnostic test
Reason: Memerlukan pemeriksaan
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.